257 results on '"Álvares-da-Silva, Mário Reis"'
Search Results
2. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium
3. Predicting liver fibrosis in Gaucher disease: Investigation of contributors and development of a clinically applicable Gaucher liver fibrosis score
4. Geographic disparities in access to liver transplant for advanced cirrhosis: Time to ring the alarm!
5. Firmicutes/Bacteroidetes and Firmicutes/Proteobacteria ratios are associated with worse prognosis in a cohort of Latin American patients with cirrhosis
6. A global research priority agenda to advance public health responses to fatty liver disease
7. Nicotinamide riboside and dietary restriction effects on gut microbiota and liver inflammatory and morphologic markers in cafeteria diet–induced obesity in rats
8. Changes in the gut microbiota of rats after exposure to the fungicide Mancozeb
9. Alcoholic liver disease and intestinal microbiota in an experimental model: Biochemical, inflammatory, and histologic parameters
10. Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study
11. New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD
12. Muscle fibre morphometric analysis (MusMA) correlates with muscle function and cardiovascular risk prognosis
13. Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease
14. Evaluation of drug-induced liver injury as etiology for acute liver failure in Brazil
15. Assessing the impact of COVID-19 on liver cancer management (CERO-19)
16. Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1–6 in Brazil
17. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease
18. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population
19. Liver involvement in patients with Gaucher disease types I and III
20. Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial
21. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
22. Elastic Fibers Density: a New Parameter of Improvement of NAFLD in Bariatric Surgery Patients
23. Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients
24. Seroprevalence of hepatitis E virus in risk populations and blood donors in a referral hospital in the south of Brazil
25. Transcranial direct current stimulation (tDCS) has beneficial effects on liver lipid accumulation and hepatic inflammatory parameters in obese rats
26. O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA
27. Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease
28. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS
29. Extracellular Vesicles and Their Correlation with Inflammatory Factors in an Experimental Model of Steatotic Liver Disease Associated with Metabolic Dysfunction.
30. HLA‐G 3′UTR haplotype analyses in HCV infection and HCV‐derived cirrhosis, hepatocellular carcinoma and fibrosis
31. Corrected integrated density: a novel method for liver elastic fibers quantification in chronic hepatitis C
32. O-2 EVALUATION OF RISK FACTORS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION
33. Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study
34. Uncovering Actions of Type 3 Deiodinase in the Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
35. Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases
36. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)
37. Protocol to segment and characterize the morphometry of individual cross-sectioned striated muscle fibers from adult murine models
38. Ornithine Aspartate and Vitamin-E Combination Has Beneficial Effects on Cardiovascular Risk Factors in an Animal Model of Nonalcoholic Fatty Liver Disease in Rats
39. O-21 EVIDENCE OF SUBOPTIMAL PUBLIC HEALTH POLICIES ON HEPATOCELLULAR CARCINOMA IN THE AMERICAS: A HUGE DEBT OF OUR REGION
40. Gut mycobiota changes in liver diseases: A systematic review.
41. Uniting the Global Gastroenterology Community to Meet the Challenge of Climate Change and Non-Recyclable Waste
42. Rifaximin prophylaxis in MASLD‑hepatocellular carcinoma: Lessons from a negative animal model.
43. Gut dysbiosis and systemic inflammation promote cardiomyocyte abnormalities in an experimental model of steatohepatitis
44. Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population
45. Hepatotoxicity by methyl methacrylate
46. Transient Hepatic Elastography in the Assessment of Liver Fibrosis in Patients After Liver Transplantation
47. Comparison Between Handgrip Strength, Subjective Global Assessment, Anthropometry, and Biochemical Markers in Assessing Nutritional Status of Patients with Crohn’s Disease in Clinical Remission
48. Bone marrow mesenchymal stem cells in acute-on-chronic liver failure grades 2 and 3 : a phase I-II randomized clinical trial
49. Time Between Start of Tacrolimus Use and Target Serum Level in Patients After Adult Liver Transplantation.
50. Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.